NESS ZIONA, Israel, Dec. 10, 2025 /PRNewswire/ — VisIC Technologies Ltd., a pioneer in Gallium Nitride (GaN) power semiconductors for electric mobility, today announced the successful second closing of its Round B funding, securing $26 million. The round was led by a global semiconductor leader, with HKMC joining as a strategic investor. This milestone reinforces VisIC’s position at the forefront of GaN innovation for EV traction inverters and strengthens its role in enabling next-generation electric mobility.
The lead investor’s focus on advancing critical semiconductor technologies complements VisIC’s proprietary D³GaN™ platform, designed to deliver unmatched efficiency, scalability, and reliability for automotive drivetrains. HKMC’s participation underscores its commitment to integrating GaN technology into mass-production EV platforms.
The global EV market is experiencing rapid growth, with automakers racing to improve driving range, reduce costs, and meet stricter sustainability targets. A critical bottleneck lies in the efficiency and scalability of power electronics, particularly traction inverters, which directly impact vehicle performance and energy consumption.
Problem Statement Traditional silicon-based solutions struggle to deliver the efficiency and power density required for next-generation EV platforms, especially at higher voltages. While SiC (Silicon Carbide) devices offer improved performance, their high cost and complex manufacturing limit widespread adoption. VisIC’s GaN-based D³GaN™ technology addresses these limitations by enabling smaller, lighter, and more efficient inverters—unlocking new possibilities for both 400V and 800V architectures.
Use of Funds The new capital will accelerate VisIC’s roadmap, including:
Optimization, qualification, and release of Gen3 750V GaN dice and power modules.
Development of Gen4 1350V GaN technology, supporting the full spectrum of EV designs.
Stabilization of the supply chain and ramp-up of GaN product delivery for EV traction inverters.
Expansion into emerging 800V data center power requirements, leveraging the same advanced GaN platform.
Executive Quotes Tamara Baksht, CEO of VisIC Technologies: “This investment marks a major milestone for VisIC and the global EV industry. Our D³GaN technology is redefining power electronics for electric vehicles, and the support of our strategic partners accelerates our mission to deliver high-efficiency, scalable solutions for the next generation of mobility.”
Hyundai Motor Company and Kia: “Hyundai Motor Company and Kiaare committed to advancing sustainable mobility. Partnering with VisIC enables us to integrate cutting-edge GaN power technologies into our EV platforms, enhancing efficiency, reliability, and performance as we shape the future of electric transportation.”
NESS ZIONA, Israel, Dec. 10, 2025 /PRNewswire/ — VisIC Technologies Ltd., a pioneer in Gallium Nitride (GaN) power semiconductors for electric mobility, today announced the successful second closing of its Round B funding, securing $26 million. The round was led by a global semiconductor leader, with HKMC joining as a strategic investor. This milestone reinforces VisIC’s position at the forefront of GaN innovation for EV traction inverters and strengthens its role in enabling next-generation electric mobility.
The lead investor’s focus on advancing critical semiconductor technologies complements VisIC’s proprietary D³GaN™ platform, designed to deliver unmatched efficiency, scalability, and reliability for automotive drivetrains. HKMC’s participation underscores its commitment to integrating GaN technology into mass-production EV platforms.
The global EV market is experiencing rapid growth, with automakers racing to improve driving range, reduce costs, and meet stricter sustainability targets. A critical bottleneck lies in the efficiency and scalability of power electronics, particularly traction inverters, which directly impact vehicle performance and energy consumption.
Problem Statement Traditional silicon-based solutions struggle to deliver the efficiency and power density required for next-generation EV platforms, especially at higher voltages. While SiC (Silicon Carbide) devices offer improved performance, their high cost and complex manufacturing limit widespread adoption. VisIC’s GaN-based D³GaN™ technology addresses these limitations by enabling smaller, lighter, and more efficient inverters—unlocking new possibilities for both 400V and 800V architectures.
Use of Funds The new capital will accelerate VisIC’s roadmap, including:
Optimization, qualification, and release of Gen3 750V GaN dice and power modules.
Development of Gen4 1350V GaN technology, supporting the full spectrum of EV designs.
Stabilization of the supply chain and ramp-up of GaN product delivery for EV traction inverters.
Expansion into emerging 800V data center power requirements, leveraging the same advanced GaN platform.
Executive Quotes Tamara Baksht, CEO of VisIC Technologies: “This investment marks a major milestone for VisIC and the global EV industry. Our D³GaN technology is redefining power electronics for electric vehicles, and the support of our strategic partners accelerates our mission to deliver high-efficiency, scalable solutions for the next generation of mobility.”
Hyundai Motor Company and Kia: “Hyundai Motor Company and Kiaare committed to advancing sustainable mobility. Partnering with VisIC enables us to integrate cutting-edge GaN power technologies into our EV platforms, enhancing efficiency, reliability, and performance as we shape the future of electric transportation.”
Members of Cambodia's delegation wave their country's national flag as they take part in the athletes' parade during the opening ceremony of the 33rd Southeast Asian Games (SEA Games) at Rajamangala National Stadium in Bangkok on December 9, 2025. (Photo by Lillian SUWANRUMPHA / AFP)
AFP – Cambodia withdrew on Wednesday from the Southeast Asian Games, an Olympic official said, as a border conflict with hosts Thailand escalated and forced a mass exodus of civilians from both sides of the disputed frontier.
At least 11 soldiers and civilians have been killed on both sides, according to officials, as renewed hostilities derailed a US-brokered truce.
Cambodia had already pulled out of eight sports at the Thailand-hosted Games, but National Olympic Committee of Cambodia (NOCC) chief Vath Chamroeun wrote in a letter Wednesday to the Southeast Asian Games Federation that it would bring all of the country’s athletes home.
“Due to serious concerns and requests from the families of our athletes to have their relatives return home immediately, NOCC must withdraw all of our delegation and arrange for their prompt return to Cambodia for safety reasons,” he wrote.
The Games officially opened on Tuesday, 9 December, and will run until 20 December in Bangkok and the nearby coastal province of Chonburi, with thousands of athletes from southeast Asian countries competing in events ranging from football and fencing to skateboarding, sailing and combat sports.
But renewed fighting this week between Thailand and Cambodia over a long-standing border dispute has overshadowed the Games.
There was tightened security at Tuesday’s opening ceremony at the Rajamangala National Stadium in Bangkok attended by Thai royals and featuring Thai K-pop idol BamBam.
A small delegation from Cambodia took part in the athletes’ parade.
This week’s clashes are the deadliest since five days of fighting in July that killed dozens before a shaky truce was agreed, in large part owing to intervention by US President Donald Trump.
Both sides blame each other for sparking the renewed clashes, which on Tuesday expanded to five provinces of both Thailand and Cambodia, according to an AFP tally of official accounts.
More than 500,000 people have fled their homes to safety in Thailand and Cambodia since the conflict reignited, both governments said on Wednesday, surpassing the total number evacuated during similar clashes earlier this year.
The dispute centres on a century-old disagreement over borders mapped during France’s colonial rule in the region, with both sides claiming a smattering of boundary temples.
SUZHOU, China, Dec. 10, 2025 /PRNewswire/ — On December 8, 2025, Alphamab Oncology (Stock Code: 9966.HK) successfully held its “Stay True to Our Original Aspiration, Forge Ahead into the Future” 2025 R&D Day in Shanghai. The event focused on the latest advancements in the field of antibody-drug conjugates (ADCs), comprehensively showcasing the company’s R&D achievements in bispecific ADCs and dual-payload ADCs. It also shared a highly differentiated and globally competitive product pipeline and clinical development strategy, while outlining the multidimensional evolution of its world-leading technology platforms and the future blueprint for ADC therapies.
The event featured attendance of several distinguished experts, including Professor Li Zhang from the Sun Yat-sen University Cancer Center, Professor Chang Chen from the Shanghai Pulmonary Hospital, Professor Jian Zhang from the Fudan University Shanghai Cancer Center, and Professor Suiwen Ye from the Sun Yat-sen Memorial Hospital. Dr. Ting Xu, Chairman and CEO of Alphamab Oncology, along with representatives from the company’s management team, also participated in the event. The thematic presentations and in-depth discussions during the conference attracted hundreds of guests from academia, industry, and the investment sector, with over a thousand participants joining online. This robust engagement fully reflects the industry’s significant interest in the company’s R&D capabilities and innovation strategy.
Professor Li Zhang provided a systematic review of the development history of ADC drugs and advancements in the treatment of non-small cell lung cancer (NSCLC). Drawing on clinical trial cases of ADC therapies, he elaborated on the current landscape and challenges in this field: drug resistance and insufficient response rates remain major challenges in lung cancer treatment. ADCs, with their “precision targeting + high efficacy killing” mechanism, have emerged as a significant breakthrough direction. However, issues such as target heterogeneity and endocytosis efficiency remain current difficulties. Professor Zhang particularly emphasized that JSKN016’s dual-target design helps broaden tumor recognition and enhance endocytosis efficiency. He highly commended the drug for achieving safety advantages, especially lower hematological toxicity, through site-specific conjugation with DAR4. While highly efficient and toxic ADCs are more suitable for later-line treatment, JSKN016 holds promise for playing a significant role in first-line therapy, either as a monotherapy or in combination with chemotherapy, targeted therapy, and immunotherapy. Its clinical studies have extensively covered lung cancer treatment from later-line to first-line (including both EGFR-mutant and wild-type cases), offering potential solutions to unmet clinical needs in NSCLC. JSKN033 is the world’s first and only bispecific ADC and PD-L1 compound formulation to enter clinical trials. Its “seconds-level” subcutaneous injection significantly enhances dosing convenience, and preliminary efficacy signals provide a novel synergistic approach of “targeted + immunotherapy” for first-line lung cancer treatment.
Professor Suiwen Ye provided a systematic analysis of the current treatment landscape and development trends for advanced triple-negative breast cancer (TNBC): TNBC is highly aggressive and carries a poor prognosis. In recent years, significant breakthroughs have been achieved in the treatment paradigm: immunotherapy first established “immunotherapy combined with chemotherapy” as a new first-line standard, while ADC drugs have led treatment into a new era of “chemotherapy-free” approaches, delivering substantial survival benefits across patient populations. The Phase I study of JSKN016 has shown encouraging efficacy in heavily pre-treated advanced TNBC patients, and its high objective response rate is expected to translate into significant improvements in progression-free survival (PFS) and overall survival (OS). Currently, the development of ADC drugs has received key support at the national level, and the global market continues to expand with promising prospects. Professor Ye believes that outstanding representatives of Chinese pharmaceutical innovation, such as Alphamab Oncology, will contribute novel treatment solutions for refractory tumors through the development of ADC pipelines like JSKN016.
Professor Chang Chen shared the research progress and innovative trends in perioperative treatment for early-stage lung cancer: The perioperative management of NSCLC has evolved from postoperative adjuvant chemotherapy to a comprehensive approach encompassing precision-targeted perioperative therapy and chemotherapy combined with immunotherapy. For patients with driver-gene-positive tumors, perioperative targeted therapy significantly reduces the risk of postoperative recurrence and effectively improves disease-free survival (DFS). For driver-gene-negative patients, the treatment model has shifted from primarily postoperative observation to a comprehensive strategy of “neoadjuvant immunotherapy combined with chemotherapy + surgery + adjuvant immunotherapy.” This model, with its significant benefits in event-free survival and overall survival, has become a global standard of care. Currently, treatment is further expanding into the field of ADCs. Studies show that neoadjuvant regimens containing ADCs demonstrate remarkable potential in improving pathological complete response (pCR) rates without increasing surgery-related risks, offering a new breakthrough direction for curing early-stage lung cancer.
During the roundtable discussion on “Trends and Prospects of ADC Drugs in Cancer Treatment,” Professor Chang Chen served as the moderator. The participating experts and Dr. Ting Xu engaged in in-depth exchanges on the current positioning, evolving role, and unmet clinical needs of ADCs in oncology therapy. In response to the challenge of resistance to first-line treatments combining ADCs with TKIs or immunochemotherapy, Professor Li Zhang proposed moving beyond the limitations of traditional chemotherapy and exploring new directions such as physical therapies, ADC expansion, nanomedicines, and cellular therapies. From the perspective of the potential toxicity of DB09 and the uncertainty of subsequent treatment options after resistance to first-line therapies, Professor Jian Zhang expressed a preference for its use as a robust later-line treatment. He recommended optimizing frontline therapies with novel bispecific drugs like KN026, thereby constructing a comprehensive treatment strategy with more balanced efficacy and safety, clearer sequential logic, and the goal of maximizing survival benefits while ensuring patients’ quality of life. Professor Suiwen Ye pointed out that ADC therapies represented by JSKN016, in combination with chemotherapy and immunotherapy, constitute a promising and worthy new direction for neoadjuvant treatment in TNBC. It is expected to achieve higher pathological complete response (pCR) rates compared to traditional standard therapies.
The experts unanimously agreed that the field of ADCs is advancing toward a new era characterized by greater precision and combination strategies. They expressed high recognition and anticipation for Alphamab’s clinical needs-driven R&D approach. They expressed confidence in the R&D philosophy that “technology determines the future, while clinical application drives progress”—that is, starting with clear clinical objectives and addressing real-world challenges, using technological innovation to solve problems. Even if validation takes time, solid technology will ultimately yield favorable outcomes.
Professor Jian Zhang, drawing on his experience participating in the early clinical development of KN026, provided an in-depth analysis of the current treatment landscape and future directions for HER2-positive and HR-positive/HER2-negative breast cancer. Existing therapies are associated with significant side effects, creating critical opportunities for KN026 and JSKN003, which may achieve a better balance between efficacy and safety. KN026 has demonstrated outstanding efficacy in HER2-positive breast cancer patients previously treated with trastuzumab/pertuzumab. The latest ESMO data in second-line gastric cancer further suggests it may possess a unique anti-tumor mechanism, heightening anticipation for its potential in first-line breast cancer treatment. Professor Zhang further elaborated on the differentiated positioning and complementary value of JSKN003 and JSKN016. JSKN003 is designed to cover both HER2-positive and HER2-low expressing populations. It not only holds promise as an important later-line treatment option but also broadens its application prospects due to its cross-tumor activity. In contrast, JSKN016 focuses on the HER2-negative domain. Its excellent efficacy and safety profile as a monotherapy facilitate combination regimens (e.g., synergistic effect without increased toxicity when combined with capecitabine). Both drugs employ an optimized DAR4 design, aiming for superior efficacy while maintaining lower toxicity. In the era of “year-long management” of breast cancer as a chronic condition, patients’ long-term treatment experience and quality of life are paramount. JSKN003 and JSKN016, developed based on the glycan-specific conjugation platform, not only demonstrate significant potential in their respective target populations but also, through exploration in frontline therapies and combination strategies, hold the promise of reshaping the breast cancer treatment landscape and providing better options for patients across different subtypes.
Dr. Ting Xu systematically introduced the company’s innovative R&D strategy, covering aspects such as technological upgrades, R&D achievements, product pipeline, and value realization. Dr. Xu stated that with the global incidence and mortality rates of cancer continuing to rise, Alphamab Oncology remains steadfastly focused on addressing unmet clinical needs. The company is committed to developing highly effective, safe, and revolutionary anti-tumor drugs, aiming to delivering China-innovated cancer therapies to benefit patients worldwide. The company’s independently built modular, iterative technology platform system and highly differentiated product pipeline serve as powerful validation of its strategic advancement and a solid commitment to future development.
Leveraging its globally leading glycan-specific conjugation platform and linker-payload platform, the company is steadily advancing a series of bispecific ADCs and dual-payload ADCs with Best-in-class and First-in-class potential. Within the HER2-targeted pipeline, the HER2 bispecific antibody KN026 continues to deepen its development in breast and gastric cancers, with the potential to change current clinical guidelines. JSKN003 has demonstrated differentiated therapeutic potential across multiple disease areas, including breast cancer, platinum-resistant ovarian cancer, colorectal cancer, and gastric cancer. Published data supports its potential to become a best-in-class therapy for platinum-resistant ovarian cancer. JSKN033, as a high-concentration subcutaneous formulation combining IO and ADC therapies, allows administration within 30 seconds, significantly enhancing the safety and convenience of ADC drugs. In the PD-L1-targeted pipeline, the PD-L1/ITGB6/8 multifunctional ADC JSKN022 demonstrates superior internalization efficiency and in vitro/in vivo killing activity compared to monoclonal antibody ADCs. The PD-L1/VEGFR2 bispecific antibody ADC JSKN027 integrates triple mechanisms of targeted chemo, anti-angiogenesis and IO. The EGFR/HER3 bispecific, dual-payload ADC JSKN021 shows superior in vivo efficacy compared to similar candidates and maintains efficacy in models insensitive to either TOPO1 or MMAE payloads. These three drugs are planned to target various globally prevalent cancers in the future, including colorectal, lung, liver, and gastric cancers, as well as head and neck squamous cell carcinoma, indicating broad clinical development prospects.
Currently, four of the company’s ADC drugs are in clinical stages, two ADC candidates are poised to enter clinical trials, eight Phase III clinical studies are progressing steadily, and three indications are nearing the stage of BLA submission. This marks the pipeline’s innovative achievements entering a phase of intensive fruition and will drive the company’s long-term value growth. Looking ahead, Alphamab Oncology will continue to promote the multi-dimensional evolution of its technology platforms, deepen the global development of bispecific and dual-payload ADCs, and continually explore the therapeutic potential and full lifecycle value of differentiated innovative molecules. The company expects that starting from 2026, it will achieve the launch of at least one new product or new indication per year, bringing more innovative therapies originating from China to the world and providing safer, more effective treatment options for global patients.
Stay true to our original aspiration, we let patient needs steer our course, transforming strategic foresight into technological breakthroughs; Forge ahead into the future, we confront refractory diseases with unwavering resolve, turning scientific exploration into therapeutic innovations. We are steadfastly advancing toward our mission: To make cancer manageable and curable.
About Alphamab Oncology Alphamab Oncology (Stock Code: 9966.HK) is an innovative biopharmaceutical company focused on oncology. Leveraging proprietary platforms-including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payloads, dual-payload ADCs, and high-concentration subcutaneous formulations, the Company has built a differentiated and globally competitive pipeline, covering cutting-edge candidates in ADCs, bispecific antibodies, and single-domain antibodies.
One product has received market approval: Envafolimab (KN035, brand name: 恩维达®), the world’s first subcutaneously injected PD-(L)1 inhibitor, offering greater convenience and accessibility in cancer treatment. The NMPA has accepted the new drug application for KN026 (Anbenitamab Injection), a HER2 bispecific antibody, for second-line or later HER2-positive gastric cancer. Four bispecific ADC candidates have entered clinical stages, and next-generation ADC pipelines—such as dual-payload ADCs—are advancing rapidly. The Company has established strategic partnerships with organizations including CSPC, ArriVent, and Glenmark, covering both product development and technology platforms.
Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, delivering China-innovated cancer therapies to benefit patients worldwide.
SHANGHAI, CHINA – Media OutReach Newswire – 10 December 2025 – The Power Station of Art announces the grand opening of Does the flower hear the bee? the 15th Shanghai Biennale on November 8th, 2025. The exhibition is curated by Chief Curator Kitty Scott, Co-curators Daisy Desrosiers and Xue Tan, as well as Curators Long Yitang and Zhang Yingying, both selected from PSA’s Emerging Curators Project. The exhibition design is led by all(zone) / Rachaporn Choochuey, Sara De Bondt is the graphic designer, and Sarah Demeuse is the editor. The City Projects of the 15th Shanghai Biennale will be open to the public at several of Shanghai’s iconic urban spaces — Jia Yuan Hai Art Museum, VILLA tbh, Shanghai, Shanghai Botanical Garden-Penjing Garden, and klee klee & friends. During the opening week, the Power Station of Art will host a series of public programs, including performances, roundtable discussions, artist workshops, and special lectures.
Like the flower that “hears” the bee’s wings, the 15th Shanghai Biennale aims to operate at the intersection of differing models of intelligence, both human and nonhuman. It is based on the belief that recent art provides us with a privileged space for such investigations, offering an embodied and interconnected sphere in which communities may form stronger bonds with “the more-than-human world.”
We live in a moment of great uncertainty and global emergency that has given rise to a widespread sense of disorientation. Our world is transforming at a pace that eludes our capacity for comprehension, leaving us feeling bewildered and uncertain. If a return to the past is impossible, art offers us potential pathways out of despair and malaise, helping us to find emergent forms-of-life and new modes of sensorial communication amid this instability.
Conceived in dialogue with the ideas of artists, curators, intellectuals, musicians, poets, scientists, and writers, Does the flower hear the bee? recognizes that much depends on our capacity to sense the world around us and attune ourselves to its diverse array of intelligences. Its hopeful vision rests on art’s ability to orient us towards an unknown future.
67 Participating Artists and Collectives from Around the World
This edition of the Biennale will feature over 250 works by 67 individual artists and collectives from around the world, including 16 from China. Over 30 works are commissioned or new.
Participating artists (listed in alphabetical order by last name):
Kim Adams, Abbas Akhavan, Allora & Calzadilla, Francis Alÿs, Ryoko Aoki, Carmen Argote, Shuvinai Ashoona, Alvaro Barrington, Lêna Bùi, Tania Candiani, Maxime Cavajani, Carolina Caycedo, Chen Ruofan, Cheng Xinhao, Sara Cwynar, Dan Er, Rohini Devasher, Miguel Fernández de Castro, Cristina Flores Pescorán, Theaster Gates, Abraham González Pacheco, Brett Graham, Hao Liang, d harding, Ho Tzu Nyen, Ngahina Hohaia, Hu Xiaoyuan, Huang Yongping, Ulala Imai, Aki Inomata, Brian Jungen, Lotus L. Kang, Amar Kanwar, Christine Sun Kim, Ragnar Kjartansson, Jaffa Lam, Lina Lapelytė, Liu Shuai, Sharon Lockhart, Liz Magor, Gordon Matta-Clark, Ari Benjamin Meyers, Audie Murray, Kosen Ohtsubo, Christian Kōun Alborz Oldham, Lisa Oppenheim, Plant South Salesroom, Qiu Shihua, R. H. Quaytman, Walid Raad, Shao Chun, Shao Fan, Heji Shin, Tan Jing, Shannon Te Ao, Luke Willis Thompson, Rirkrit Tiravanija, Gözde Mimiko Türkkan, Hajra Waheed, Evelyn Taocheng Wang, Xu Tiantian, Ami Yamasaki, Haegue Yang, Masaomi Yasunaga, Cansu Yıldıran, Gozo Yoshimasu, Zhou Tao
* Maxime Cavajani and Theaster Gates participate in the Biennale’s City Project at the Jia Yuan Hai Art Museum. The works of Rirkrit Tiravanija, Chen Ruofan, and Zhou Tao are on display at both the Power Station of Art and the Biennale’s City Project at the Jia Yuan Hai Art Museum. Liu Shuai participates in the Biennale’s City Project at the Jia Yuan Hai Art Museum and VILLA tbh, Shanghai.
Exhibition Design: Walking a Garden-Like Landscape
The 15th Shanghai Biennale centers on interactions between different life forms. The exhibition unfolds as an open landscape—a space to wander through rather than move along. Artworks seed throughout the Power Station of Art—anchored in the grand hall, threaded through circulation paths, tucked into enclosed rooms and gallery spaces. It is not a path to follow but a terrain to inhabit—where artworks, architecture, and visitors co-exist in shifting relations.
The scenography treats the building itself as landscape. Raw concrete blocks—the same industrial vocabulary as the architecture—form a man-made terrain throughout the space. Like rockwork in a garden that shapes how you see the scenery, these blocks offer different vantage points for viewing the artworks. They are utilitarian and designed for a second life: after the exhibition, they can be upcycled rather than discarded.
The design takes its cue from gardens—not as decoration, but as spatial principle. Like a Chinese scholar garden or Japanese stroll garden, the exhibition reveals itself progressively. As you move through, sightlines shift and new compositions emerge. Enclosed rooms offer moments of immersion, a different quality of attention. There is no prescribed route, only invitation. The exhibition offers moments to wander, to stop, not to rush but to rest and reflect among others. Visitors become part of the ecology—another life form moving through and shaping the space. The exhibition design team, all(zone) / Rachaporn Choochuey trusts visitors to find their own rhythm—generous enough to wander in, structured enough to discover. These pauses aren’t interruptions but essential, acknowledging that attention deepens with time, that reflection happens in stillness as much as in movement.
Exhibition Publications
The accompanying catalogue and the reader of this edition will be published concurrently with the exhibition. The 400-page catalogue prioritizes the participating artists’ voices, features essays by the three curators and includes extensive documentation of exhibited works, while occasional interludes punctuate the book as propositions for future sounds, poems, or languages.
The reader brings together artists, scholars, and writers, who explore emergent modes of receptivity, from listening as a sustained practice and forms of attending to the human and the nonhuman, to consciousness of materiality and ephemerality. Together, the texts open a range of affective, communicative, and embodied registers.
City Projects
The City Projects of the 15th Shanghai Biennale aim to have a generative momentum. Beginning at PSA, the projects progressively summon, relocate, displace, and spread into multiple landscapes—from garden fences in urban neighborhoods (e.g., VILLA tbh) to open fields on the outskirts (Jia Yuan Hai Art Museum), from carefully cultivated bonsai in botanical gardens (Shanghai Botanical Garden) to native grasses growing freely on balcony gardens (klee klee)—and over the course of the exhibition, will reach further corners of Shanghai…
These back-and-forth passages resemble successive and affective “bee paths.” As the public experiences art in different places, every pause, touch, and conversation helps catalyze the mingling of art and everyday rhythms — eventually, through perception, movement, and encounter, one quietly attunes to those “moments of abundance.”
City Projects Exhibition Information for the 15th Shanghai Biennale
Does the flower hear the bee? (Extended Version) Artists: Maxime Cavajani, Chen Ruofan, Theaster Gates, Liu Shuai, Rirkrit Tiravanija, Zhou Tao Time: November 8, 2025 – March 31, 2026 (Tuesday–Sunday, 09:30–17:30; closed on Monday) Venue: Jia Yuan Hai Art Museum, No. 39 Dazhi Road, Jiading District, Shanghai
The flight map of these affective journeys along both banks of the Huangpu River converges at the Jia Yuan Hai Art Museum in Jiading, Shanghai. Designed by Japanese architect Tadao Ando with a philosophy of dialogue between architecture, nature, and the human, the museum becomes a site where works by Maxime Cavajani, Chen Ruofan, Theaster Gates, Liu Shuai, Rirkrit Tiravanija, and Zhou Tao form another kind of resonance with land, architecture, light, and sound.
Slide, Then Soar! Artist: Liu Shuai Time: November 9, 2025 – January 4, 2026 (Monday–Sunday, 10:00–18:00) Venue: VILLA tbh, No. 15 Taojiang Road, Xuhui District, Shanghai
At VILLA tbh on 15 Taojiang Road, Xuhui, artist Liu Shuai presents Slide, Then Soar!, a commission for the 15th Shanghai Biennale. In a small, hovering form, it poetically engages the garden-world’s everyday nature—kites collaged from plants, and bamboo reeds punctured by bees and are repurposed as an instrument. Through a human–nature collaboration, the work responds to the Biennale’s query in Does the flower hear the bee?
Ami Yamasaki — Special Performance Time: November 8, 15:00 Venue: Penjing Garden, Shanghai Botanical Garden
Participating artist Ami Yamasaki stages a site-specific performance in the Penjing Garden of the Shanghai Botanical Garden, continuing her exploration of acoustic space and reciprocal listening. Treating the human voice as a method of locating oneself in the world, and the body as a vessel that resonates with space, the artist situates herself through singing, listening, and echo, gradually dissolving the subject–site boundary and inviting audiences to co-establish new sensitivities.
Ami Yamasaki — Special Performance & Exhibition Opening (mid-December) Venue: klee klee & friends, 2F, Building 3, Columbia Circle, No. 1626 West Yan’an Road, Shanghai Performance Time: November 10, 10:00; Exhibition Dates: Mid-December
At klee klee’s “Wilderness Balcony,” Ami Yamasaki’s special performance serves as a prelude to the winter exhibition, telling the journey of a seed: eaten and carried afar by birds, eventually returning to the soil to quietly take root and grow into a sapling amid the grasses. This is not only a cycle of life; it also offers a micro testimony of how the “grass store,” the birds, and humans share the same sky, soil, forests, and fields—like the quiet yet abundant atmosphere at the instant when the flower meets the bee.
About the Shanghai Biennale
Launched in 1996, the Shanghai Biennale is not only the first international biennial of contemporary art in the Chinese mainland but also one of the most influential art events in Asia. In 2012, the Power Station of Art became the organizer and permanent venue of the Shanghai Biennale. From Open Space in 1996, to Inheritance and Exploration in 1998, Spirit of Shanghai in 2000, Urban Creation in 2002, Techniques of the Visible in 2004, Hyper Design in 2006, Translocalmotion in 2008, Rehearsal in 2010, Reactivation in 2012, Social Factory in 2014, Why Not Ask Again in 2016, Proregress in 2018, Bodies of Water in 2020, and Cosmos Cinema in 2023, the Biennale has always maintained Shanghai as its primary locus, upholding the mission of supporting academic and cultural innovation, while continuously tracking social evolution and trends in knowledge production in a global context with an open view. Taking place in Shanghai every two years, the Biennale has also become a large-scale platform for the international presence and exchange of contemporary art.
About the Shanghai Biennale City Projects
As a unique urban event and cultural landmark, the Shanghai Biennale has long been committed to enabling active dialogues between contemporary art and the booming city of Shanghai. First launched in 2012, the Biennale’s City Projects interact with public spaces such as exhibition pavilions, cinemas, and cultural centers, mobilizing local actors to explore the regional context through shows, screenings, field surveys, and workshops. This program aims to extend the Biennale beyond the museum and establish a closer relationship with the city’s residents and its cultural ecology.
The 15th Shanghai Biennale: Does the flower hear the bee?
Chief Curator: Kitty Scott Co-curators: Daisy Desrosiers, Xue Tan Curators: Long Yitang, Zhang Yingying Exhibition Design: all(zone) / Rachaporn Choochuey Graphic Designer: Sara De Bondt Editor: Sarah Demeuse
Venue: Power Station of Art City Project Partner: JIA YUAN HAI, tbh, Shanghai Botanical Garden, klee klee Special Partner: Aesop Official Travel Partner: DENZA Official Hotel Partner: The Langham, Shanghai, Xintiandi and Brilliant by Langham
The issuer is solely responsible for the content of this announcement.
About the Power Station of Art (PSA)
Established on Oct 1, 2012, the Power Station of Art (PSA) is the first state-run contemporary art museum in the Chinese mainland. It is also home to the Shanghai Biennale. Formerly the Nanshi Power Plant, the now renovated PSA was once the Pavilion of Future during the 2010 Shanghai World Expo. Having witnessed Shanghai’s transformation from the industrial age to the digital era, the museum’s raw architecture has provided rich inspiration for artists. As a central hub for Shanghai’s booming urban culture, PSA is committed to innovation and progress as keys to its long-term vitality. The museum aims to provide an interface for the public to come into contact with and appreciate contemporary art, to break down the barrier between life and art, and to promote cooperation and knowledge production across diverse fields of arts and culture.
DKSH Business Unit Healthcare Launches a three-part whitepaper series to help healthcare and life science companies explore industry trends and current market pressures to re-think commercial go-to market approaches in the Asia Pacific region. The whitepaper series demonstrates how strategic Commercial Outsourcing partnerships are evolving to deliver sustainable growth, resource agility, and improved patient access – successfully harnessing the region’s growing USD 10 billion healthcare outsourcing opportunity.
SINGAPORE, Dec. 10, 2025 /PRNewswire/ — DKSH Business Unit Healthcare has developed its “2025 Whitepaper Series on Commercial Go-To-Model Trends”, exploring how Commercial Outsourcing can transform go-to-market strategies for healthcare and life science companies across the APAC region. The three-part series shares how Commercial Outsourcing is able to manage fragmented regulations, pricing challenges and evolving patient expectations without bigger fix investment in infrastructure – freeing internal teams to focus their higher impact priorities like innovation and strategic launches while helping patients receive life-changing therapies and treatments when they need it, where they need it. The series draws insights from research surveying more than 50 senior leaders across pharmaceuticals, biotech, and MedTech as well as in-depth interviews with several senior industry decision makers.
To help companies navigate this landscape, DKSH Business Unit Healthcare has released its “2025 Whitepaper Series on Commercial Go-To-Model Trends“. The first section examines why traditional commercial models are faltering in fragmented and cost-pressured markets, and why companies are reassessing their go-to-market strategies. Its sequel explores how organizations can evaluate potential partners and decide what potential product portfolios and commercial functions create the most value when outsourced. The final part outlines the capabilities, governance, data readiness, and digital tools needed to sustain high-performing partnerships over time. The research reveals that 90% of executives already outsource some part of their business, with 62% having increased outsourcing in the past three years.
“The APAC healthcare landscape is changing, and our research shows that traditional commercial models are no longer enough to meet the growing demands of patients in our region. As APAC’s healthcare ecosystem leaders – we must rethink how we go to market,” said Patrik Grande, Vice President, Commercial Outsourcing Head, APAC, DKSH Healthcare. “Commercial Outsourcing is emerging as a strategic go-to market approach because it enables faster market access, operational flexibility, and compliance excellence. It is not just about reducing costs; it is about unlocking growth and resources.”
The Whitepaper series was unveiled at a launch event in Singapore attended by close to 100 healthcare regional leaders, with DKSH experts sharing commercial insights and executive panel discussions moderated by EY Parthenon exploring perspectives from across the industry.
“Commercial Outsourcing is a key enabler for global healthcare companies to expand their products and services into markets faster while still addressing key factors, such as pricing and compliance,” said Reuben Ong, Vice President, Singapore, DKSH Healthcare, during the panel discussion. “One such example was when DKSH partnered with a leading global healthcare company to transition to a commercial outsourcing model. We grew their portfolio by 25%, consistently achieved performance targets and, most importantly, improved healthcare accessibility to patients across the region.”
Together, the insights point to a clear shift underway in Asia’s healthcare landscape. Organizations that invest in stronger partnerships, smarter capabilities, and locally grounded execution will shape the region’s next wave of access and innovation. DKSH will continue supporting partners with the expertise and scale needed to navigate this shift and unlock sustainable growth across Asia-Pacific.
The “2025 Whitepaper Series on Commercial Go-To-Model Trends” is available for download here.
About DKSH Healthcare
For 160 years, DKSH has been delivering growth for companies in Asia and beyond across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services, following its purpose of enriching people’s lives. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 28,060 specialists, generating net sales of CHF 11.1 billion in 2024. As a strategic healthcare business partner, DKSH Business Unit Healthcare distributes and commercializes pharmaceuticals, consumer health, and over-the-counter products as well as medical devices. With around 8,000 specialists, Business Unit Healthcare generated net sales of CHF 5.7 billion in 2024. www.dksh.com
Demonstration underscores Europe’s commitment to secure, resilient, multi-orbit military satellite communications
SINT-NIKLAAS, Belgium, Dec. 10, 2025 /PRNewswire/ — ST Engineering iDirect’s EU Satcom Centre of Excellence, ST Engineering iDirect Europe, based in Sint-Niklaas, Belgium, today announced that the European Protected Waveform (EPW) consortium has successfully completed over-the-air testing, marking a critical milestone in Europe’s pursuit of strategic autonomy in secure military communications. Conducted on November 26-27, 2025 at Universität der Bundeswehr München, Germany, the demonstrations validated EPW’s ability to safeguard military satellite communications against jamming, cyber threats, and unauthorised access across both GEO and LEO satellite configurations.
Demonstration underscores Europe’s commitment to secure, resilient, multi-orbit military satellite communications
Belgian National Armaments Director, Major General Filip Borremans, highlighted the importance of this milestone, “The successful EPW demonstrations perfectly illustrate the mission of the European Defence Fund, enabling Member States to achieve collectively what none could accomplish alone. By uniting 19 partners from 13 nations, the consortium has demonstrated that European collaboration delivers both technical excellence and strategic autonomy. Secure satellite communications are a cornerstone of modern defence, and EPW proves that through coordinated European investment, we can develop sovereign solutions that strengthen our collective security.”
This milestone underscores the critical need for standards-based, interoperable, secure communications in modern military operations. As cyber threats from state and non-state actors intensify and missions span increasingly dispersed theaters, robust and resilient infrastructure has become indispensable. Designed with security, agility, efficiency, and interoperability at its core, the EPW empowers European military forces to maintain secure communications—whether operating independently or in coalition—adapting seamlessly to diverse operational demands and geographic challenges.
Co-funded by the European Union through the European Defence Fund, the programme unites industry and academia from across Europe under the leadership of Belgium’s Ministry of Defence, with ST Engineering iDirect Europe as the consortium lead. This collaborative effort is tackling both current and emerging challenges in military satellite communications, including evolving security threats, growing demands for higher throughput, and the need for enhanced mobility solutions.
“The EPW consortium’s successful completion of this major milestone, demonstrated live and witnessed by supporting military end-users, represents a critical step toward the next phase of the EPW programme,” said Koen Willems, Vice President, EU Programmes, at ST Engineering iDirect Europe. “This achievement paves the way for the prototyping and testing of the final capability, which will deliver secure and resilient communications for Europe. It underscores the consortium’s unwavering commitment to advancing Europe’s strategic autonomy in military communications through innovation and collaboration.”
The European Protected Waveform is funded by the European Union. Views and opinions expressed are however those of ST Engineering iDirect Europe only and do not necessarily reflect those of the European Union or the European Commission. Neither the European Union nor the granting authority can be held responsible for them.
About the European Protected Waveform (EPW) Program The European Protected Waveform is a European Defence Fund program co-funded by the European Union, with a total estimated cost of €29.9 million and a maximum EU contribution of €25 million. Over its 39-month duration, the program aims to develop secure waveform standards for future-proof satellite communications, addressing challenges such as joint and dispersed operations, mobility requirements, and the integration of both GEO and NGSO satellites.
About the European Defence Fund The European Defence Fund (EDF) supports collaborative defense research and development projects across EU Member States, strengthening Europe’s technological and industrial defense capabilities while promoting cooperation and interoperability.
About ST Engineering iDirect Europe
ST Engineering iDirect Europe, located in Sint-Niklaas, Belgium, is ST Engineering iDirect’s EU Satcom Center of Excellence specialising in the development of ground segment technology and solutions specifically for the EU. As a legal Belgian entity, ST Engineering iDirect Europe has its own board of directors to comply to the guidelines and conditions as put forward by the EU Commission and the Belgian Government. With over 35 years of experience, the ST Engineering iDirect portfolio of high-value product lines and services in addition to a dedicated team of domain specialists, and a ISO9001 certified manufacturing center the team has a portfolio of capabilities to cater to the specific needs of European funded satcoms programs.
JOHOR BAHRU, MALAYSIA – Media OutReach Newswire – 10 December 2025 – Novotel, the brand dedicated to creating meaningful moments of balance for business and leisure travellers, proudly announces the opening of Novotel Johor Bahru City Centre, a new addition to the city’s growing hospitality scene. Ideally located in the heart of Johor Bahru, the hotel offers a harmonious blend of contemporary comfort, warm Malaysian hospitality, and thoughtful touches for guests of all ages.
Above: Family Room
The hotel’s interiors subtly weave elements of Malaysia’s cultural identity into a modern, stylish setting, creating inviting spaces that reflect local character while embracing Novotel’s signature contemporary flair.
The hotel features 304 thoughtfully designed rooms and suites with floor-to-ceiling windows, Smart TVs, Deep Nature amenities, and flexible layouts. Suites include espresso machines, while family room configurations ensure an enjoyable stay for all.
Guests can dine at Food Exchange, offering local favourites, international cuisine, and festive menus. The Gourmet Bar in the lobby serves light bites, crafted drinks, and grab-and-go options, while the Pool Bar offers refreshments beside the open-air infinity pool.
For meetings and events, the hotel presents The Grand Chamber, a pillarless 520 square metre ballroom equipped with three LED screens, accommodating up to 300 guests. Six additional meeting rooms and a VIP waiting room make the hotel an ideal venue for weddings, conferences, and corporate gatherings.
“The opening of Novotel Johor Bahru City Centre reflects our continued commitment to growing Accor’s presence across Asia,” said Garth Simmons, Chief Operating Officer, Premium, Midscale & Economy Division, Accor Asia.“Johor Bahru is a dynamic gateway city, and this hotel embodies the balance of comfort and modernity that Novotel is known for. We are proud to introduce a property that elevates the city’s hospitality offering and supports Malaysia’s wider tourism growth.”
“We are thrilled to open Novotel Johor Bahru City Centre as a vibrant new destination for travellers and the local community,” said Brendan Chong, General Manager. “Our goal is to create meaningful stays where business meets comfort in the heart of Johor Bahru.”
The hotel’s debut beautifully complements the excitement surrounding Visit Malaysia 2026 and Visit Johor 2026, inviting travellers to discover Johor Bahru through the lens of comfort, culture, and contemporary hospitality.
As part of Novotel’s long-term commitment to ocean longevity, the hotel reflects the brand’s belief that human wellbeing and planetary wellbeing go hand in hand. In 2024, Novotel launched a Positive Impact Plan, grounded in UN ocean-related actions, to reduce plastic, water, and carbon impacts; and promote sustainable food choices through plant-forward menus. At Novotel Johor Bahru City Centre, this commitment comes to life with filteredwater taps in every room, providing unlimited purified drinking water while eliminating single-use plastic bottles and contributing to healthier oceans.
To celebrate the opening, guests can enjoy an Exclusive Opening Offer starting from MYR 345++ per night , valid for stays from today until 6 March 2026.
Members of ALL Accor, the all-in-one booking platform and award-winning loyalty program can enjoy exclusive benefits and earn reward points during their stay at Novotel Johor Bahru City Centre. Points can be redeemed for future stays, dining, and unique experiences across Accor’s global network. Enrolment is free at all.com.
The issuer is solely responsible for the content of this announcement.
About Novotel
Novotel Hotels, Suites & Resorts offers high-quality hotels designed as comforting and energising places where guests can achieve balance in their busy lives, whether they are traveling for work, leisure or a blend of both. The brand’s wide array of hotels, suites and resorts offer a multitude of services, including spacious, modular rooms with natural and intuitive design; relaxed restaurants with nutritious choices; flexible workspaces; attentive and proactive staff; family zones for the youngest guests; multi-purpose lobbies; and accessible fitness centres. Novotel, which has over 600 locations in more than 60 countries is part of Accor, a world leading hospitality group counting over 5,700 properties throughout more than 110 countries, and a participating brand in ALL Accor, a booking platform and loyalty program providing access to a wide variety of rewards, services and experiences.
https://www.powerstationofart.com/
https://www.linkedin.com/company/power-station-of-art/
https://www.instagram.com/powerstationofart/
https://all.accor.com/hotel/B585/index.en.shtml
https://www.facebook.com/profile.php?id=61582145394566
https://www.instagram.com/novoteljbcc/
